Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes
Authors' conclusion
We conclude that symptomatic hypoglycemia was more commonly reported by the tirzepatide-treated group compared to the semaglutide-treated group, while gastrointestinal AEs were comparable between groups. We recommend that individualized risk assessment and close supervision on insulin dose changes are required when prescribing off-label tirzepatide or semaglutide in adults with T1D.
Study context
- Population
- Overweight or obese adults with T1D using tirzepatide or semaglutide as adjunctive therapy, Barbara Davis Center for Diabetes
- Participants
- 230 participants
- Exposure
- Adjunctive tirzepatide vs semaglutide
- Outcome
- Real-world AEs associated with tirzepatide or semaglutide use
Methodological detailssingle-centre, real-world
- Single-centre
- Real-world
Main finding
As reported in the abstract
Symptomatic hypoglycaemia
P < 0.001
Observational data: associations, not effects.
Further findings
Baseline characteristics by sex · initiation
- Baseline mean body weight, males vs females (P < 0.01)
- 107.8 ± 18.9 kg vs. 89.6 ± 19.2 kg
- Age, males vs females (P < 0.05)
- 44.2 ± 12.2 years vs. 40.4 ± 11.5 years
Gastrointestinal adverse event (AEs) by age and sex
- Young adults and females more likely to report gastrointestinal AEs regardless of medication
Safety
Symptomatic hypoglycaemia · more frequent with tirzepatide
P < 0.001
Original publication
Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. Diabetes Technol Ther. Published 10 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →